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Graphical abstract 
 
Abstract 
Amphiphilic block copolymers, PEG-PBLA with different molecular weights, were 
synthesized and used as new stabilizers for Itraconazole nannosuspensions 
(ITZ-PBLA-Nanos). ITZ-PBLA-Nanos were prepared by the microprecipitation-high 
pressure homogenization method, and the particle size and zeta potential were 
measured using a ZetaSizer Nano-ZS90. Morphology and crystallinity were studied 
using TEM, DSC and powder X-ray. The effect of the PEG-to-PBLA ratio, and the 
drug-to-stabilizer ratio were investigated to obtain the optimal formulation. It was 
found that the optimal length of hydrophobic block was 25 BLA-NCA molecules and 
the optimal ratio of drug/stabilizer was 1:1, where the resulted average particle size of 
ITZ-PBLA-Nanos was 262.1±7.13 nm with a PDI value of 0.163±0.011. The images 
of TEM suggest that ITZ-PBLA-Nanos were rectangular in shape. ITZ existed as 
crystals in the nanoparticles as suggested by the DSC and XRD results. Compared 
with the crude drug suspensions, the dissolution rate of ITZ nanocrystals, was 
significantly increased and was similar to Sporanox® injection. The ITZ-PBLA-Nanos 
also demonstrated better dilution stability and storage stability compared with 
ITZ-F68-Nanos. The particle size of ITZ-PBLA-Nanos did not change significantly 
after incubated in rat plasma for 24 h which is a good attribute for I.V. administration. 
Acute toxicity tests showed that ITZ-PBLA-Nanos has the highest LD50 compared 
with ITZ-F68-Nanos and Sporanox® injection. ITZ-PBLA-Nanos also showed 
stronger inhibiting effect on the growth of Candida albicans compared with 
Sporanox® injection. Therefore, PEG-PBLA has a promising potential as a 
biocompatible stabilizer for ITZ nanosuspensions and potentially for other 
nanosuspensions as well. 
Key words: PEG-PBLA, Nanosuspension, Itraconazole, Microprecipitation-high 
pressure homogenization method, Stability, Acute toxicity, Antifungal activity 
 
 
 
 
 
 
 
 
 
1. Introduction 
Itraconazole (ITZ) is a weakly basic (pKa=3.7) triazole antifungal agent and 
antiparasitic agent with a broad spectrum of activity, and is used in the treatment of 
both local and systemic fungal infections including: blastomycosis (pulmonary and 
extrapulmonary), histoplasmosis (chronic cavitary pulmonary, and disseminated 
non-meningeal), aspergillosis (pulmonary and extrapulmonary), as well as 
onychomycosis of the finger and toenails (Beule and Gestel, 2001; Boogaerts and 
Maertens, 2001). It has poor solubility in water (~1 ng/mL at neutral pH, ~4 μg/mL at 
acidic pH) (Janssens et al., 2007; Peeters et al., 2002). ITZ is a well-known BCS class 
II compound with limited oral bioavailability and is not suitable for intravenous 
application in the conventional solution form due to its poor solubility. In the 
commercial intravenous ITZ injection, Sporanox® injection (Janssen Pharmaceuticals, 
Titusville, NJ, USA), 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) is used to increase 
the solubility of itraconazole. However, there has been a warning against the use of 
Sporanox® injection in renally impaired patients (Rabinow et al., 2007), due to the 
side effects of the solubilizer HP-β-CD, rather than the drug itself. It is a common 
issue that the treatment of fungus infections by broad antifungal agents is often 
hindered by their side effects (Rabinow et al., 2007). Therefore, it would be desirable 
to have alternative formulations without HP-β-CD and its associated side effects for 
the i.v. administration of ITZ. 
Itraconazole has well-defined quantitative correlation between its in vitro minimum 
inhibitory concentration (MIC) and clinical performance in the treatment of some 
fungal infections. Higher dose of the drug is a great advantage as it would subject 
more microorganisms from the resistant category to the “susceptible dependent upon 
dose” group, resulting in improved therapeutic outcomes (Rex et al., 1997). In other 
words, microorganisms in the resistant group may become susceptible to the drug if 
the dose is high enough. Therefore, a good formulation of ITZ should have the ability 
to deliver a high dose safely, potentially raising corresponding plasma levels above 
the MIC. 
 In the last decade, nanosuspension technology has been utilized to deliver the 
poorly soluble ITZ at high loadings in some studies (De Smet et al., 2014; Sarnes et 
al., 2014). Nanosuspensions are colloidal dispersions stabilized by various 
electrostatic or steric stabilizers where the particles are in the range of sub-microns 
(Pu et al., 2009b). Nanosuspensions are considered to be a suitable alternative in the 
formulation of BCS class-II drugs with low solubility due to their high dissolution 
velocity and high loading capacity (Kassem et al., 2016; Liu et al., 2016; Shah et al., 
2016). Although there are various advantages of using nanosuspensions for the 
delivery of BCS II drugs, poor physical stability has been a key drawback (Wang et al., 
2016). Nanosuspensions are thermodynamically unstable due to the interfacial energy 
associated with the huge surface area of particles and the particles may settle or 
aggregate over time resulting in increased particle size. The particle size may also 
change due to crystal growth or change of crystal form (Chavhan., 2013; Gao et al., 
2007).  
As indicated by the Ostwald-Freundlich equation (Pu et al., 2009a), the stability of 
nanosuspensions is directly affected the particle size and particle size distribution. 
Narrow particle size distribution will reduce the differences in the saturated solubility 
between small and large particles in nanosuspensions, and thus slowing down the 
Ostwald ripening process. Stability can be improved by modifying the surface 
property of the particles with appropriate stabilizers. Stabilizers could provide steric 
and electrostatic repulsion in order to prevent aggregation. Various stabilizers have 
been used in ITZ Nano disperse systems, including poloxamer 407 (Matteucci et al., 
2006), HPMC (Matteucci et al., 2007; Matteucci et al., 2009), poloxamer 188 and 
sodium deoxycholate (Rabinow et al., 2007), poly(vinyl alcohol) and glycyrrhizic 
acid (Fernández-Ronco et al., 2015), Tween 80 (Wlaz et al., 2015), HPMC and SDS 
(Azad et al., 2016) and Tween 20 (Foglio Bonda et al., 2016) . However, formulations 
using these stabilizers have their limitations, such as large size up to a micron or 
unknown stability, and are not suitable for intravenous administration as they could 
bring potential safety issues (Decuzzi et al., 2010; Pu et al., 2012). To overcome such 
limitations, it is desirable to have new stabilizers that are able to adsorb onto the 
surface of the particles more firmly and hence providing better stabilizing effect. It is 
generally accepted that developing new stabilizers is an important aspect of 
nanosuspension technology (Wang et al., 2013). 
Effective stabilization performance requires a stabilizer to have the following two 
properties. It should have a suitable hydrophobic moiety which provides the driving 
force for the adsorption of stabilizers onto the surface of newly formed nanoparticles 
in order to achieve rapid and sufficient stabilization. It should also have a substantial 
hydrophilic moity which could orient toward the water phase forming an effective 
hydration layer to isolate neighboring nanoparticles. Poly(amino acids), a kind of 
biodegradable polymers, possess wonderful biocompatibility and have been widely 
applied in tissue engineering (Deng et al., 2005), polymer micelles (Zhao et al., 2012), 
liposomes (Park et al., 2013), and so on. Polyethylene 
glycol-poly(β-benzyl-L-aspartate) (PEG-PBLA) is one of the poly(amino acids) that 
possesses suitable hydrophile-lipophile properties that can be utilized to stabilize 
nanoparticles. 
In this study, PEG-PBLA block copolymers of different molecular weights were 
selected as stabilizers to prepare ITZ-Nanos. It has been used in other drug delivery 
systems, including micellar delivery systems (Bae et al., 2007; Kataoka et al., 2000; 
Li et al., 2010; Pu et al., 2014), but as far as we are aware, it has not been used as a 
stabilizer for pharmaceutical nanosuspensions. In this study, the PEG-PBLA block 
copolymers were firstly synthesized and characterized, and then a combination of 
microprecipitation and high-pressure homogenization method was used to prepare the 
PEG-PBLA stabilized nanoparticles (ITZ-PBLA-Nanos). Physicochemical properties, 
acute toxicity, and antifungal activities of the ITZ-PBLA-Nanos were then evaluated 
and compared with ITZ-F68-Nanos.  
2. Materials and Methods 
2.1. Materials 
Amine-terminated poly(ethylene glycol) monomethyl ether (MPEG-NH2) was 
purchased from Shanghai Seebio Biotech，Inc. (Shanghai, China). L-aspartate acid 
was obtained from Shanghai Kaiyang Biological Technology Co. Ltd. (Shanghai, 
China). Triphosgene was provided by Shanghai Ruiteng Chemical Industry Co. Ltd. 
(Shanghai, China). All organic reagents for synthesis of PEG-PBLA were dehydrated 
by means of circulation reflux with Calcium hydroxide before use. Itraconazole was 
purchased from Shanghai Yuanye Biological Technology Co. Ltd. (Shanghai, China). 
Sporanox® injection was the product of Xian Janssen Pharmaceutical Ltd. (Xian, 
China). Potato dextrose medium and agar were purchased from Huayueyang 
Biotechnology (Beijing) Co. Ltd. (Beijing, China). All other reagents were of 
analytical grade. 
2.2. Synthesis of PEG-PBLA of different PEG-to-PBLA ratios 
The method for the synthesis of PEG-PBLA of different PEG-to-PBLA ratios was 
adapted from the published methods (Bae et al., 2007; Li et al., 2010; Okonya et al., 
1995; Pu et al., 2014), which involve three steps as briefly described below. 
2.2.1. Synthesis of β-Benzyl-L-aspartate (BLA) 
L-aspartic acid (21.6 g, 0.16 mol) and 120 mL benzyl alcohol were added to a dry 
glass reactor and 10 mol/L hydrochloric acid (15 mL) was injected dropwise into the 
solution. The mixture was heated at 65 ℃ with constant stirring for 3 h and the 
resultant water was removed under reduced pressure. More 10 mol/L hydrochloric 
acid (7.5 mL) was added in order to continue the reaction. After the reaction was 
complete, the reactive mixture was cooled with ice water, and anhydrous ethanol (400 
mL) was added and the pH was adjusted to 6 using triethylamine. The precipitate 
formed was washed with ethanol and acetone and subsequently dried under vacuum at 
40 ℃. The coarse product was recrystallized in 70 ℃ hot water to obtain the white 
solid BLA. 
2.2.2. Synthesis of BLA-NCA 
BLA (4.46 g, 20 mmol) and triphosgene (2.97 g, 10 mmol) were suspended in 60 
mL anhydrous tetrahydrofuran (THF) under nitrogen atmosphere and the mixture was 
stirred at 40 ℃ for 3 h till the solution became transparent. Anhydrous petroleum ether 
was gently poured into the reaction liquid which was maintained at -20 ℃ overnight 
and the resulting precipitates were collected. The precipitates were further purified 
through recrystallization in a mixture of anhydrous THF and n-hexane (1/3, v/v). 
2.2.3. Synthesis of block copolymer PEG-PBLA 
BLA-NCA and MPEG-NH2 were added to moderate amount of anhydrous 
methylene chloride (5wt% to NCA monomer) and stirred for 72 h under nitrogen 
atmosphere at room temperature. The mixture was then added to excess amount of 
anhydrous diethyl ether and the precipitates were collected and further purified by 
recrystallization in a mixture of methylene chloride and anhydrous diethyl ether. 
PEG-PBLA with different PEG-to-PBLA ratios (10/1, 25/1, and 50/1) were achieved 
by setting the molar concentration ratio of BLA-NCA monomer and initiator 
MPEG-NH2 to 10/1, 25/1 and 50/1. 
2.3 Characterization of block copolymer PEG-PBLA 
1H NMR spectra were recorded on an AVANCE 400 MHz spectrometer (Bruker 
Optics, BioSpi, Switzerland). IR analyses were carried out with an Avatar 360 Fourier 
transform infrared spectrophotometer (Nicolet Instrument Corporation, Madison, 
America) using KBr pellets. Gel permeation chromatography (GPC) measurements 
were performed on an Optilab rEX Gel Permeation Chromatographer (Wyatt 
Technology Corporation, Santa Barbara, USA). 
2.4. Preparation of nanosuspensions and crude suspensions 
ITZ PEG-PBLA nanosuspensions (ITZ-PBLA-Nanos) were prepared by 
microprecipitation-homogenization method. Firstly, 100 mg ITZ and 100 mg 
PEG-PBLA were completely dissolved in 2 mL of DMSO at 60 ℃ to form the good 
solvent phase. The antisolvent phase (50 mL water) was stirred at 1500 rpm using a 
magnetic stirrer (Gongyi City Yuhua Instrument Co., Ltd., Gongyi, Henan, China) at 
room temperature. The good solvent phase was rapidly injected into the antisolvent 
phase to form a coarse suspension which was continuously stirred for 10 min after the 
injection was completed. Concentrations of PEG-PBLA and ITZ were both 2 mg/mL. 
This coarse suspension was then homogenized for five cycles at 250 bar followed by 
another five cycles at 500 bar through the NS1001L2K high-pressure homogenizer 
(Niro Soavi S.p.A. Co, Parma, Italy). Finally, the suspension was homogenized for 25 
cycles at 1000 bar where an equilibrium plateau in size was reached. After a 
cryoprotectant (Mannitol, 5%, w/v) was added, the nanosuspensions were frozen at 
-20 ℃ for 12 h in a freezer and subsequently lyophilized in a Christ Alpha 1-2 LD plus 
freeze-dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode, Germany) at 
-50 ℃ for 40 h to obtain a dry powder. The dry ITZ-PBLA-Nanos were reconstituted 
in 0.9% saline where applicable. 
Nanosuspensions of blank control were prepared by the same method as described 
above, except that ITZ was not added. 
ITZ nanosuspensions stabilized by poloxamer 188 (F68), i.e. ITZ-F68-Nanos, were 
prepared with a drug-to-polymer ratio (1:1) using the same method as described above, 
except that PEG-PBLA was replaced by F68. 
Crude ITZ suspensions were prepared by dispersing bulk ITZ and PEG-PBLA(1/25) 
in water with a mass ratio of 1:1 using a high speed rotary homogenizer (Shanghai 
Specimen Model Factory, China) at 5000 rpm. 
2.5. Particle size and zeta potential 
Particle size, polydispersity index (PDI), and zeta potential were measured using a 
ZetaSizer Nano-ZS90 (Malvern Instruments, Malvern, UK) based on dynamic light 
scattering. Each sample was measured in triplicate, and the average was taken. The 
ITZ-PBLA-Nanos were reconstituted in water for injection prior to the measurements. 
2.6. Particle morphology 
The dimension and morphology of particles were observed using transmission 
electron microscope (TEM). Freshly prepared samples were dropped onto a 
carbon-coated copper grid and air-dried at room temperature. Images were taken 
using a JEOL 2010 TEM (JEOL Co., Japan) at a tension of 80 kV. 
2.7. X-ray diffraction (XRD) 
An X-ray power diffractometer (D8-Advance, Bruker AXS, Germany) was 
employed to obtain the X-ray diffraction patterns of freeze-dried nanoparticles. The 
X-ray generator was set at 30 mA and 40 kV to generate the Cu Ka radiation 
(monochromator: graphite). The following samples were packed into the rotating 
sample holder between two films (PETP) to obtain the X-ray diffraction patterns: 
physical mixture of PEG-PBLA and mannitol (also referred to as “blank excipients”), 
lyophilized ITZ-PBLA-Nanos, crude ITZ, and physical mixture of ITZ and 
PEG-PBLA. The spectra were typically collected with a step width of 0.04 ° and a 2 θ 
range scanned between 5 ° and 50 ° at a rate of 6 °/min. 
2.8. DSC analysis 
The differential scanning calorimetry (DSC) of the formulations was investigated 
with a TA-60WS Thermal Analyzer (Shimadzu, Japan). Briefly, moderate amount of 
samples were added into aluminum pans and sealed with pinhole-pierced covers. An 
empty aluminum pan was used as a reference. Each sample was scanned at a heating 
rate of 10 ℃/min from 30 to 250 ℃ with a N2 flow rate of 20 mL/min. The same 
samples as described in the X-ray diffraction section were studied. 
2.9. In vitro dissolution 
A ZRS-8G dissolution apparatus (Tianjin University Radio Factory, Tianjin, China) 
was used to test the in vitro dissolution profile. The paddle method as specified in the 
Chinese Pharmacopoeia 2015 was employed. Briefly, ITZ-PBLA-Nanos, Sporanox® 
injection and the crude ITZ suspensions, each contained 10 mg ITZ, were added to 
500 mL phosphate buffer (pH 7.4) containing 5% (w/v) SDS at 37 ℃ and the rotation 
speed of the paddle was set at 75 rpm. At a pre-determined time of 2, 5, 15, 30, 45, 60 
and 120 min, 5 mL of the dissolution medium was withdrawn and replaced with 5 mL 
of fresh medium of the same temperature. Samples were filtered through 0.45 µm 
filters and drug concentrations were measured by HPLC. Sink conditions were 
maintained throughout the testing period. All experiments were performed in triplicate. 
The statistical differences were tested by similarity factor comparison method (f2) 
which is a model-independent test. 
2.10. Stability study 
1.10.1. Storage stability 
The reconstituted ITZ-PBLA-Nanos were stored at 4 ℃ in a refrigerator and room 
temperature for a week, and the particle sizes were measured and compared with 
ITZ-F68-Nanos. Approximately 2 mL samples were collected for analysis and the 
particle sizes at 0, 1, 2, 3, 5 and 7 days were measured. All measurements were 
carried out in triplicates. 
2.10.2. Dilution stability 
To study the effect of dilution on the particle size stability, ITZ-PBLA-Nanos and 
ITZ-F68-Nanos were diluted 10, 50, 100 times with water for injection and the 
particle sizes of the samples were measured using a Malvern Zeta Sizer as described 
above. All experiments were performed in triplicate. 
2.10.3. Stability in plasma 
The reconstituted ITZ-PBLA-Nanos and ITZ-F68-Nanos were mixed with rat 
plasma in equal volumes, and the mixtures were incubated at 37 ℃ in an incubator 
(ZWY-103D, Shanghai Zhicheng, China) with the shaker speed set at 150 rpm. At a 
pre-determined time of 0.083, 1, 3, 5, 10 and 24 h, 2 mL of the mixture was 
withdrawn and the particle size and PDI were measured. All samples were measured 
in triplicates. 
2.11. Acute toxicity 
Studies of acute toxicity of ITZ-PBLA-Nanos were carried out in a facility with 
official approval of the Animal Care and Use Committee of Henan University, China. 
Seven to eight weeks old Kunming mice (18-22 g) were individually housed in 
suspended stainless steel cages with free access to food and water. Access to food was 
removed 12 h prior to administration and subjects were randomly divided into fifteen 
groups (n=6). Sporanox® injection (at 40, 70, 100, 130, and 160 mg/kg), itraconazole 
nanosuspensions (including ITZ-PBLA-Nanos and ITZ-F68-Nanos, both at 60, 110, 
160, 210, and 260 mg/kg) were administered intravenously via a caudal tail vein at 
approximately 1 mL/min. The negative control mice were given physiological saline. 
Animals were observed for any adverse clinical signs immediately and approximately 
1 h following infusion, and daily thereafter for the duration of the study. Individual 
body weights were determined prior to infusion and on the 2nd, 4th, and 7th days. The 
LD50 of each group was obtained using SPSS 19.0 software (International Business 
Machines Corporation, America). The statistical differences were tested using a 
two-tailed Student t-test. 
2.12. In vitro antifungal activity 
The antifungal activity of ITZ-PBLA-Nanos and Sporanox® injection was evaluated 
with Candida albicans (gift from Professor Wangjun Yuan at Henan University, China) 
by disk diffusion method and viable cell counting method in vitro. In both methods, 
frozen fungi was inoculated in a pre-sterilized potato dextrose medium and activated 
for 24 hours before antifungal experiments. 
 
In the disk diffusion methods, 8 mL of Candida albicans suspension was mixed well 
with liquefied and sterilized potato dextrose agar (PDA) medium (100 mL), and 30 
mL of the mixture was poured into petri dishes for painting nutrient agar plates. After 
solidified, sterile round filter papers with uniform size were evenly placed at 
predetermined spots according to the experimental design. Formulaitons of different 
concentrations of ITZ were transferred to the filter papers (5 μL/piece). After 
incubation at 28 ℃ for 24 h, the diameter of the inhibition zone surrounding each of 
filter papers was observed and recorded (cm). 
The viable cell counting method was employed to further verify the results of disk 
diffusion method. Briefly, aliquots of ITZ formulations were added to 50 mL of potato 
dextrose medium to reach final concentrations of 250, 100, 50, 25, 10 μg/mL. 
Candida albicans were incubated in a potato dextrose medium at 28 ℃, and diluted as 
appropriate, to reach an OD600 value of 0.4. Then the Candida albicans suspension 
was diluted ×5 times with sterile water to obtain the final suspension for assay. One 
mL of the final suspension was added to petri dishes and mixed with the PDA which 
contained different concentrations of ITZ. After the mixtures solidified, they were 
incubated for 24 h at 28 ℃. The experiment was run in triplicate. Afterward, the 
colonies were counted and the number of colony units (CFU/mL) was computed by 
the following formula. Statistical differences were tested using a two-tailed Student 
t-test. 
Number of colony units (CFU/mL) = Cm×D×5 
Where Cm is the mean of colony number in three plates, and D is dilution factor. 
2.13. Determination of ITZ 
ITZ concentrations in dissolution medium were determined using a Waters 2695 
HPLC system (Waters Corporation, Milford, USA) equipped with an autosampler and 
a variable wavelength UV detector. A reverse-phase C-18 column (5 µm, 250 mm×4.6 
mm, Thermo Syncronis) was used and the temperature was maintained at 25 ℃. The 
mobile phase consisted of methanol and water (85:15, v/v) and the flow rate was 1.0 
mL/min. The wavelength was 263 nm and 20 µL sample was injected into the column 
for analysis. Calibration curves (0.1-100 µg/mL) were prepared using ITZ standard 
solutions in methanol. 
3. Results and Discussion 
3.1. Synthesis and characterization of PEG-PBLA 
The synthesis of PEG-PBLA is schematically shown in Scheme 1. BLA was first 
synthesized by the reaction of L-aspartic and benzyl alcohol. NCA was subsequently 
synthesized from BLA and triphosgene. MPEG-NH2 was used as an initiator to 
initiate NCA ring opening polymerization and produce PEG-PBLA. PEG-PBLA of 
different molecular weights were achieved by adjusting the feed molar ratio between 
MPEG-NH2 and NCA, such as PEG-PBLA (1/10), PEG-PBLA(1/25), 
PEG-PBLA(1/50). The structures of the copolymers were confirmed by 1H-NMR and 
IR, and the molecular weight was tested with gel permeation chromatography (GPC). 
The results proved the formation of the PEG-PBLA diblock copolymers according to 
the IR spectra (Fig. S1) and NMR spectra (Fig. S2). The obtained polymers with 
different molecular weights (data are shown in Fig. S3) were used to prepare 
itraconazole nanosuspensions. 
  The polymerization process was monitored by IR and considered to be complete 
when the peaks (1863 and 1786 cm-1) of BLA-NCA disappeared. The two new peaks 
at 1658 cm-1 and 1554 cm-1 were ascribed to the amide I and amide Ⅱ bond of the 
peptide bonds as shown in Fig. S1 which indicate that the ring-opening 
polymerization was successful. The data of NMR are shown below, indicating that 
PEG-PBLA was obtained, in agreement with the IR study. 
  BLA-NCA 1H-NMR(DMSO) δ=8.98(s, NH, 1H), 7.36(m.ArH, 5H), 5.13(s, ArCH2, 
2H), 2.91(s, CH2NH, 2H) 
  PEG-PBLA 1H-NMR(CDCl3) δ=8.86(s, NH, 1H), 7.26(m.ArH, 5H), 5.13(s, ArCH2, 
2H), 4.28(s, COCH, 1H), 3.64(m, CH2, 2H), 3.38(s, CH3, 3H), 2.88(s, CH2NH, 2H) 
3.2. Formulation of ITZ nanocrystals   
Table 1 shows the particle size and PDI of ITZ nanoparticles stabilized with PBLA 
copolymers of different segment ratios, PEG-PBLA(1/10), PEG-PBLA(1/25) and 
PEG-PBLA(1/50). It could be clearly seen that ITZ nanosuspensions with 
PEG-PBLA(1/25) exhibited the smallest particle size and the size did not increase 
during the seven day study period. Although the PDI of this formulation was not the 
smallest freshly after preparation, it did not increase in the seven day study period and 
remained below 0.224. The PDI of the nanosuspensions stabilized with PEG-PBLA 
(1/10) and PEG-PBLA (1/50) increased significantly, from 0.078 to 1 and from below 
0.137 to over 0.505, respectively. The results indicate that PEG-PBLA(1/25) has the 
best stabilization effect. In order to stabilize nanosuspensions effectively, strong and 
fast adsorption of the stabilizer onto the new surface at full coverage to slow down the 
growth of fine crystals is required (Choi et al., 2005). The hydrophobic interaction 
between the stabilizers and the nanoparticles is the driving force for the adsorption of 
stabilizers onto the surface of a drug. Therefore, the hydrophobic section of the 
stabilizer should be large enough to ensure effective adsorption (Lee et al., 2005). In 
addition, the stabilizers should also have a strong hydrophilic section to ensure the 
formation of a steric stabilization layer of the hydrophilic polymer chains. Such a 
hydrophilic chain layer could form stabilizing barriers between approaching particles 
through: a) entropic changes due to the reduced conformational freedom of the 
polymer chains , b) enthalpic changes due to the release of hydrated water molecules 
from the polymer chains, and c) localized osmotic pressure due to increased 
concentration of polymer chains in the overlapping region (Florence and Attwood, 
1998; Hunter and Chan, 1987). Therefore, it is required that the amphiphilic stabilizer 
should have the right balance between the hydrophilic section and the hydrophobic 
section to ensure effective adsorption of polymers onto the particle surface and the 
formation of a substantial hydrophilic chain layer around particles. Among the three 
stabilizers used in this study, the PEG-PBLA (1/10) has the smallest hydrophobic 
section (PBLA), and hence the hydrophobic section could be too weak for it to adsorb 
onto the particles effectively, and possibly that is why it did not stabilize the 
nanoparticles well. However, when the hydrophobic segment of the polymers is too 
long, such as PEG-PBLA(1/50), the polymers will have strong intermolecular 
hydrophobic affinity, poor solubility and relatively weak hydrophilic properties, 
which do not favour the formation of an effective steric stabilization layer either. 
Another factor affecting the adsorption of polymers on to the surface of particles is 
the molecular weight. It has been reported that the adsorption rate of stabilizers 
decreases with an increase in the molecular weight of the steric stabilizer (Ghosh et al., 
2011), which is another reason why PEG-PBLA(1/50) did not stabilize the 
nanoparticles well. PEG-PBLA(1/25) has the best segment ratio as suggested by its 
best stabilizing effect and was chosen as the stabilizer for the rest of the study. 
Table 2 shows particle size and PDI of nanosuspensions at different drug-to- 
stabilizer ratios, freshly after preparation and after stored for seven days at 4°C. The 
samples with drug-to-stabilizer ratio 2:1 had the largest particle size (478.1 nm), 
which increased substantially after seven days storage (1816 nm). Sufficient quantity 
of stabilizers are needed to provide sufficient coverage of the surface of the drug 
particle, in order to establish effective steric repulsion (Ghosh et al., 2012). It is likely 
that the stabilizer in this sample was insufficient, resulting in inadequate steric 
stabilization, and hence the observed large particle size, and increase in particle size. 
The drug-to-polymer ratio of 1:1 demonstrated the smallest particle size and the least 
increase in particle size after stored for seven days. The same was observed for the 
PDI. This is because the high concentration of the stabilizer allows more stabilizer 
molecules to be adsorbed onto the surface of the particles resulting in better steric 
stabilization. However, further increase in stabilizer concentration to a 
drug-to-stabilizer ratio 1:2 resulted in a larger size (324.9 nm) and a greater increase 
in size after seven days storage than the sample with drug-to-stabilizer ration of 1:1, 
implying that the highest concentration does not necessarily provide the best 
stabilizing effect. It is generally well accepted that the stabilizer concentration is very 
important in stabilizing the nanoparticles (Wang et al., 2013) and need to be optimized 
for a given drug/polymer system. In this study the results have shown that the 
drug-to-polymer ration 1:1 is the best. 
3.3. Particle size, zeta potential and morphology 
Particle size is an important factor affecting the sedimentation of particles. 
According to Stokes law, the sedimentation rate is directly proportional to the square 
of the size, hence a reduced size is strongly preferable for a nanosuspension. In 
addition to the mean particle size, particle size distribution is also an important factor 
affecting the stability of a nanosuspension. A broad size distribution tends to facilitate 
Ostwald ripening, resulting in a rapid growth of crystals and the aggregation of 
particles (Wang et al., 2013). In this paper, we studied the mean particle sizes, PDI 
and zeta potentials of ITZ-PBLA-Nanos in comparison with ITZ-F68-Nanos. 
Poloxamer 188 was chosen as a comparator as it is the only polymeric amphiphilic 
stabilizer that has been reported for use in intravenous ITZ nanosuspensions so far 
(Rabinow et al., 2007). As shown in Table 3, the mean diameter of ITZ-PBLA-Nanos 
was about 262 nm, and the PDI was about 0.163, similar to that of ITZ-F68-Nanos 
(274nm, 0.201). After lyophilization, the average particle size and polydispersity of 
both PBLA- and F68-Nanos did not change dramatically compared with those prior to 
lyophilization. 
The zeta potential of ITZ-PBLA-Nanos was also similar to that of ITZ-F68-Nanos 
and remained virtually unchanged after lyophilization. Zeta potential is essential to 
the stability of colloidal dispersions, and it has been reported that a zeta potential of 
approximately -20 mV is sufficient to stabilize a nanosuspension system (Liang and 
Binner, 2008; Pu et al., 2009b). The lyophilized ITZ-PBLA-Nanos only showed a 
small increase in size (about 10 nm, data not shown) after stored at 4℃ for 30 days, 
confirming that lyophilzation is a feasible means to improve long term stability of 
ITZ-PBLA-Nanos. TEM images as shown in Fig. 1 also confirm that the size of 
ITZ-PBLA-Nanos was essentially not affected by the lyophilization process. 
Also can be seen from Fig. 1 is the morphology of ITZ-PBLA-Nanos. ITZ in the 
nanosuspension exhibited a rectangular form, different to the bulk drug which was of 
a claviform form. The observed morphology of ITZ-PBLA-Nanos is similar to that 
reported by Wong (Wong et al., 2006). The particle size of ITZ-PBLA-Nanos 
observed by TEM (Fig. 1) was in good agreement with that from DLS (262.1±7.13 
nm) and was more than an order smaller than the bulk drug (1-5 μm). The mean 
particle size of ITZ-PBLA-Nanos in this study is substantially smaller than the 
reported Poloxamer-stabilized nanosuspensions prepared using a different method 
(Rabinow et al., 2007). A small particle size is advantageous as it could help ITZ 
dissolve quickly in blood and reduce the clearance by the monocyte phagocytic 
system (MPS), which may increase the circulation time of the ITZ in the body (Gao et 
al., 2008). 
3.4. Crystalline state of ITZ 
The XRD patterns of the crude ITZ, blank excipients, physical mixture of ITZ and 
PEG-PBLA, and lyophilized ITZ-PBLA-Nanos are shown in Fig. 2. Both the crude 
ITZ and the physical mixture of ITZ and excipients demonstrated obvious diffraction 
peaks between 10° and 30°, although the peaks in the physical mixture were weaker. 
This suggests that they were both crystalline. Lyophilized ITZ-PBLA-Nanos powder 
also showed diffraction peaks in the range described above, which confirmed that the 
lyophilized powder remained crystalline. However, the pattern of peaks observed in 
the lyophilized samples was different to that from the crude ITZ. It has been shown by 
others (Cares-Pacheco et al., 2014; Grohganz et al., 2013; Kaialy and Nokhodchi, 
2013; Lee et al., 2011) that the excipient mannitol is crystalline after lyophilized and 
our own results also showed this (data not shown). The contribution from mannitol in 
the ITZ-PBLA-Nanos explains why the peak pattern of the ITZ-PBLA-Nanos was 
different from that of the crude ITZ. Fig. 3 shows the DSC results of the pure ITZ, the 
excipients, physical mixture of ITZ and PEG-PBLA, and lyophilized 
ITZ-PBLA-Nanos. It can be seen that crude ITZ exhibited a sharp endothermic peak 
at 168.63 °C. In the physical mixture, the ITZ peak was at 166.10 °C which drifted 
2.53 °C to the left due to the mixing with PEG-PBLA. An endothermic peak was 
observed at 167.54 °C for the lyophilized ITZ-PBLA-Nanos, which indicates that 
ITZ-PBLA-Nanos was crystalline, consistent with the XRD study.  
3.5. In vitro dissolution 
In this study, the dissolution rate of ITZ-PBLA-Nanos, in comparison with the 
crude ITZ suspensions and Sporanox® injection, was investigated. Typical cumulative 
dissolution profiles are shown in Fig. 4. The cumulative dissolution of 
ITZ-PBLA-Nanos was up to 89% within 2 min, similar to that of the Sporanox® 
injection which is 91% within 2 min. However, the dissolution was much slower for 
the crude ITZ suspensions and only 27% was dissolved within 2 h. The enhanced 
dissolution of the nanosuspension was due to the markedly enlarged total surface area 
and enhanced saturation solubility of ITZ associated with smaller particle size of the 
nanoparticles compared with that of the crude suspensions (Kassem et al., 2016; Li et 
al., 2016; Shah et al., 2016; Xu et al., 2016; Yang et al., 2014). While the dissolution 
profile of the ITZ-PBA-Nanos was essentially the same as Sporanox® injection, the 
toxicity of the nanosuspension was greatly reduced because of the better 
biocompatibility of PEG-PBLA than that of cyclodextrin in Sporanox® injection (see 
the acute toxicity section below). 
3.6. Stability study  
Fig. 5 shows the particle size stability of ITZ-PBLA-Nanos and ITZ-F68-Nanos at 
room temperature and at 4°C. The size of ITZ-PBLA-Nanos increased at room 
temperature from 262.1 nm to about 342.2 nm while that of ITZ-F68-Nanos increased 
more significantly from 274 nm to 422.4 nm within one week. At 4°C, the size of the 
ITZ-PBLA-Nanos effectively did not increase while that of ITZ-F68-Nanos increased 
from 274 nm to 368.7 nm. These results clearly show that ITZ-PBLA-Nanos had 
better storage stability than ITZ-F68-Nanos. 
Fig. 6. Shows the dilution stability of ITZ-PBLA-Nanos and ITZ-F68-Nanos. The 
particle size of ITZ-PBLA-Nanos did not change significantly when diluted up to 100 
times, but that of ITZ-F68-Nanos increased from 274 nm to 375.3 nm. These suggest 
that PEG-PBLA has better stabilizing effect than F68 against dilution, possibly 
because it adsorbs onto the surface of nanoparticles more strongly than F68. It has 
been suggested previously that dilution of nanosuspensions may cause the loss of 
stabilizers from the surface of the particles which in turn results in reduced stability as 
indicated by an increase of particle size (Deng et al., 2010). 
In order to confirm if the adsorption of PEG-PBLA on the surface of nanoparticles 
is stronger than that of F68, liquid nanosuspensions stabilized by PEG-PBLA, and 
F68, without cryoprotectant were purposely prepared and subjected to centrifugation 
at 53667 g for 10 min (Allegra 64R centrifuge, Beckman Coulter Inc., Brea, U.S.A). 
The precipitates collected after centrifugation were subjected to IR analysis. As can be 
seen from Fig. 7, the characteristic absorption peak of F68 (2887.44 cm-1, 1467.83 
cm-1, 1344.38 cm-1, 1147.68 cm-1, 1112.93 cm-1) no longer exist in the IR spectrum of 
precipitates from F68 stabilized nanosuspensions, suggesting that substantial F68 
could have been lost in the supernatant after centrifugation. In contrast, strong 
characteristic absorption peaks of PEG-PBLA (3300.20 cm-1, 1739.79 cm-1, 1658.78 
cm-1, 1168.86 cm-1) can be seen clearly in the IR spectrum of precipitates from 
ITZ-PBLA-Nanos. This suggests that PEG-PBLA is firmly absorbed on the surface of 
the nanoparticles and remained in the precipitates after centrifugation. As a further 
test, the liquid suspensions without cryoproctant were also lyophilized directly 
without centrifugation and the lyophilized powders were subjected to IR analysis. The 
characteristic peaks of F68 were substantially smaller in the precipitates in 
comparison to those in the lyophilized powder (Fig. S4a), suggesting the amount of 
F68 in the precipitate was smaller than that in the lyophilized powder. This further 
confirmed that substantial amount of F68 was lost in the centrifugation process. In 
contrast, the characteristic peaks of ITZ and PEG-PBLA are virtually the same for 
both the precipitates and the lyophilized powders, further confirming no substantial 
loss of the stabilizer PEG-PBLA in the centrifugation process (Fig. S4b). In addition, 
lyophilization of the supernatants proved that there were substantial amount of 
residual solid material from the supernatant from F68 stabilized nanosuspensions 
whereas the solid residue from PEG-PBLA stabilized nanosuspensions was minimal 
(Fig. S5a, S5b). IR analysis confirmed that the solid residues were F68 and 
PEG-PBLA respectively (Fig. S6). This further confirmed F68 was lost substantially 
more than PEG-PBLA during the centrifugation process, supporting the idea that 
PEG-PBLA adsorb on to the particle surface more strongly than F68. 
There are several possible reasons why the adsorption of PEG-PBLA is stronger 
than F68 taking into consideration of the structural differences between two 
stabilizers. Firstly, the mass ratio of hydrophobic section (PBLA) in PEG-PBLA is 
about 70%, higher that of the F68 (PPO, 20%), meaning that the hydrophobic 
interaction between PEG-PBLA and the surface of the nanoparticles could be stronger 
that F68. This would help PEG-PBLA to remain on the surface of the nanoparticles, 
preventing the nanocrystals from growing up or aggregate (Deng et al., 2010). 
Secondly, there are a terminal amino group and many imino groups in the PBLA 
section which could form hydrogen bound with the carbonyl group on the ITZ 
promoting stronger adsorption in addition to the general hydrophobic interactions. 
Poloxamer, on the other hand, does not have any active hydrogen in hydrophobic 
segment (PPO) to form hydrogen bond with ITZ to promote adsorption. So the 
affinity of PEG-PBLA with ITZ nanoparticle would be stronger than that of 
Poloxamer. Finally, though F68 also contains hydrophobic and hydrophilic groups, its 
hydrophobic section was sandwiched between two hydrophilic chains. In such a 
structure, the steric repulsive force of two hydrophilic chains does not favor the 
formation of a well-oriented adsorption layer around the particles (Pu et al., 2013), 
resulting in a relatively weak adsorption of F68 compared with PEG-PBLA. 
Good stability upon dilution obviously is desirable for the purpose of intravenous 
administration, and it is also important that the nanoparticles remain stable when 
mixed with plasma. So the stability of ITZ-PBLA-Nanos in plasma was studied in 
comparison with ITZ-F68-Nanos. As shown in Fig. 8, the particle size and PDI of 
ITZ-Nanos did not change significantly after mixed with rat plasma for 24 h, which 
suggests that they could remain stable when administered intravenously. 
3.7. Acute toxicity 
Table 4 shows the observations in the acute toxicity study. All animals treated with 
130 mg/kg and 160 mg/kg Sporanox® injection, 260 mg/kg ITZ-PBLA-Nanos or 
ITZ-F68-Nanos either died within a few minutes of IV dosing or were humanly killed 
as they were moribund. The incidence of death was markedly reduced when the dose 
was reduced (Table 4). At a dose level of 60 mg/kg ITZ, animals in the 
ITZ-PBLA-Nanos group did not show any toxicity symptoms, while many animals in 
the ITZ-F68-Nanos groups showed polyuria, lethargy and convulsions immediately 
after treatment. These symptoms disappeared in the surviving animals within an hour. 
For animals in the Sporanox® injection group, polyuria and lethargy were observed at 
a dose level as low as 40 mg/kg. In the groups of 70 mg/kg Sporanox® injection and 
110, 160 and 210 mg/kg ITZ-PBLA-Nanos or ITZ-F68-Nanos, the animals showed 
lethargy, irregular breathing and convulsions immediately after injection, but these 
symptoms disappeared by the following day. During the delayed observations of 
surviving animals for 1 to 7 days post-injection, it was found that red paw, black tails 
and polydipsia occurred in some animal in the groups of 70 mg/kg, 100 mg/kg 
Sporanox® injection and 160 mg/kg, 210 mg/kg ITZ-PBLA-Nanos or ITZ-F68-Nanos. 
No group differences were apparent for body weight gain over the 7-day duration of 
the study for the 40 mg/kg, 70 mg/kg Sporanox® injection groups and the 60 mg/kg, 
110 mg/kg ITZ-PBLA-Nanos or ITZ-F68-Nanos groups. However, there was a 
decreased body weight gain over the 7-day period for the 100 mg/kg Sporanox® 
injection groups and the 260 mg/kg ITZ-PBLA-Nanos or ITZ-F68-Nanos groups. 
The LD50s obtained using SPSS 19.0 software for ITZ-PBLA-Nanos, 
ITZ-F68-Nanos and Sporanox® injection are 176.60 mg/kg, 157.68 mg/kg, 68.39 
mg/kg, respectively. These results indicate that ITZ-PBLA-Nanos are more 
biocompatible (>2-fold) than Sporanox® injection, which could be explained by the 
absence of 2-hydroxypropyl-β-cyclodextrin in the ITZ-PBLA-Nanos and potentially 
improved biodistribution of the nanoparticles compared to the cyclodextrin-containing 
formulations. Furthermore, the LD50 of ITZ-PBLA-Nanos was 1.10-fold greater than 
that of ITZ-F68-Nanos. This may be partly attributed to improved biocompatibility of 
ITZ-PBLA-Nanos due to its smaller particle size and better stability than that of 
ITZ-F68-Nanos (see the stability study section). The LD50s also indicate that 
PEG-PBLA is of relatively good biocompatibility. Overall, ITZ-PBLA-Nanos 
exhibited a significantly improved tolerability in-vivo and better systemic safety than 
Sporanox® injection. 
3.8. In vitro antifungal activity 
Fig. 9 shows the results of antifungal tests by disk diffusion method. In Fig. 9A, 
it can be seen that the diameter of the inhibition zone increased with an increase of 
ITZ concentration in ITZ-PBLA-Nanos which indicated that the angifungal effect of 
the nanosuspensions was dependent on drug concentration. Fig. 9B shows that the 
inhibition zones of Sporanox® injection were larger but fuzzy compared to the 
ITZ-PBLA-Nanos. Fig. 9C shows more intuitively that the inhibition zones of 
Sporanox® injection were blurrier than those of nanosuspensions. Obviously fungi 
were more effectively inhibited by the ITZ-PBLA-Nanos in the inhibition zone as the 
zones were clearer, but the actual zones were smaller than those of the corresponding 
Sporanox® injection. Therefore, it is quite difficult to ascertain which of the two 
formulations has stronger antifungal effect from this set of results alone. Table 5 
shows the results of antifungal activity against Candida albicans by the plate count 
method. It can be seen that the number of colony units in the fungal samples treated 
by nanosuspensions and Sporanox® injection was dependent on drug concentration 
and all were significantly smaller than that in the blank control. The number of colony 
units in the samples treated by nanosuspensions was smaller than those treated by 
Sporanox® injection at all the three different concentrations tested, suggesting that the 
nanosuspensions have stronger antifungal activity than Sporanox® injection. The 
reason for this is not clear, but could be due to the potential interaction of the fungi 
with the nano particle and time-dependent localized release of ITZ surrounding the 
particles, which warrant further studies in the future. 
4. Conclusions 
  Biocompatible amphiphilic PEG-PBLA block copolymers with different 
PEG-to-PBLA ratios were synthesized in this study which could be used as stabilizers 
for ITZ nanosuspensions. PEG-PBLA with a PEG-to-PBLA ratio of 1/25 at a 
drug-to-polymer ratio of 1:1 demonstrated the best stabilizing effect. The 2-hour 
cumulative dissolution of itraconazole nanosuspensions was 3.3 times that of crude 
drug suspensions and close to the commercial itraconazole injection, Sporanox® 
injection. Compared with Sporanox® injection, ITZ-PBLA-Nanos demonstrated better 
biocompatibility with a higher LD50, avoiding the toxicity caused by beta cyclodextrin. 
Compared with ITZ-F68-Nanos, ITZ-PLBA-Nanos showed better stability and the 
acute toxicity study showed that ITZ-PBLA-Nanos are better tolerated with higher 
LD50 and better systemic safety. The antifungal effect of ITZ-PBLA-Nanos was 
dependent on drug concentration and was stronger than that of Sporanox® injection. 
The above results indicate that PEG-PBLA is a promising stabilizer for ITZ 
nanosuspensions and potentially for other insoluble drugs as well. 
Acknowledgements 
We are grateful for the financial support from the National Nature Science 
Foundation of China (No. U1304826), Science and Technology Development Project 
of Henan Province (No. 152102310077), and Key Project of Science and Technology 
Research of Henan Provincial Department of Education (No. 14A350003, 14B350012, 
13A350092). 
References 
Azad, M., Moreno, J., Bilgili, E., Dave, R., 2016. Fast dissolution of poorly water soluble drugs from 
fluidized bed coated nanocomposites: Impact of carrier size. Int J Pharm 513, 319-331. 
Bae, Y., Nishiyama, N., Kataoka, K., 2007. In vivo antitumor activity of the folate-conjugated 
pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic 
compartments. Bioconjug Chem 18, 1131-1139. 
Beule, K.D., Gestel, J.V., 2001. Pharmacology of Itraconazole. Drugs 61, 27-37. 
Boogaerts, M., Maertens, J., 2001. Clinical Experience with Itraconazole in Systemic Fungal Infections. 
Drugs 61, 39-47. 
Cares-Pacheco, M.G., Vaca-Medina, G., Calvet, R., Espitalier, F., Letourneau, J.J., Rouilly, A., Rodier, 
E., 2014. Physicochemical characterization of D-mannitol polymorphs: the challenging surface energy 
determination by inverse gas chromatography in the infinite dilution region. Int J Pharm 475, 69-81. 
Chavhan, S., 2013. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for 
bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. 
Drug Dev Ind Pharm 39, 733-743. 
Choi, J.-Y., Yoo, J.Y., Kwak, H.-S., Uk Nam, B., Lee, J., 2005. Role of polymeric stabilizers for drug 
nanocrystal dispersions. Current Applied Physics 5, 472-474. 
De Smet, L., Saerens, L., De Beer, T., Carleer, R., Adriaensens, P., Van Bocxlaer, J., Vervaet, C., 
Remon, J.P., 2014. Formulation of itraconazole nanococrystals and evaluation of their bioavailability in 
dogs. Eur J Pharm Biopharm 87, 107-113. 
Decuzzi, P., Godin, B., Tanaka, T., Lee, S.Y., Chiappini, C., Liu, X., Ferrari, M., 2010. Size and shape 
effects in the biodistribution of intravascularly injected particles. J Control Release 141, 320-327. 
Deng, C., Rong, G., Tian, H., Tang, Z., Chen, X., Jing, X., 2005. Synthesis and characterization of 
poly(ethylene glycol)-b-poly (l-lactide)-b-poly(l-glutamic acid) triblock copolymer. Polymer 46, 
653-659. 
Deng, J., Huang, L., Liu, F., 2010. Understanding the structure and stability of paclitaxel nanocrystals. 
Int J Pharm 390, 242-249. 
Fernández-Ronco, M.P., Salvalaglio, M., Kluge, J., Mazzotti, M., 2015. Study of the Preparation of 
Amorphous Itraconazole Formulations. Cryst Growth Des 15, 2686-2694. 
Florence, A.T., Attwood, D., 1998. Physicochemical Principles of Pharmacy. Am J Pharm Educ 70, 
122. 
Foglio Bonda, A., Rinaldi, M., Segale, L., Palugan, L., Cerea, M., Vecchio, C., Pattarino, F., 2016. 
Nanonized itraconazole powders for extemporary oral suspensions: Role of formulation components 
studied by a mixture design. Eur J Pharm Sci 83, 175-183. 
Gao, L., Zhang, D., Chen, M., Duan, C., Dai, W., Jia, L., Zhao, W., 2008. Studies on pharmacokinetics 
and tissue distribution of oridonin nanosuspensions. Int J Pharm 355, 321-327. 
Gao, L., Zhang, D., Chen, M., Zheng, T., Wang, S., 2007. Preparation and characterization of an 
oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm 33, 
1332-1339. 
Ghosh, I., Bose, S., Vippagunta, R., Harmon, F., 2011. Nanosuspension for improving the 
bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int 
J Pharm 409, 260-268. 
Ghosh, I., Schenck, D., Bose, S., Ruegger, C., 2012. Optimization of formulation and process 
parameters for the production of nanosuspension by wet media milling technique: Effect of Vitamin E 
TPGS and nanocrystal particle size on oral absorption. Eur J Pharm Sci 47, 718-728. 
Grohganz, H., Lee, Y.Y., Rantanen, J., Yang, M., 2013. The influence of lysozyme on mannitol 
polymorphism in freeze-dried and spray-dried formulations depends on the selection of the drying 
process. Int J Pharm 447, 224-230. 
Hunter, R.J., Chan, D.Y.C., 1987. Foundations of Colloid Science. Clarendon Press. 
Janssens, S., de Armas, H.N., Remon, J.P., Van den Mooter, G., 2007. The use of a new hydrophilic 
polymer, Kollicoat IR (R), in the formulation of solid dispersions of Itraconazole. Eur J Pharm Sci 30, 
288-294. 
Kaialy, W., Nokhodchi, A., 2013. Freeze-dried mannitol for superior pulmonary drug delivery via dry 
powder inhaler. Pharm Res 30, 458-477. 
Kassem, M.A., ElMeshad, A.N., Fares, A.R., 2016. Enhanced Solubility and Dissolution Rate of 
Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and 
Optimization Using Box-Behnken Design. AAPS PharmSciTech, 1-14. 
Kataoka, K., Matsumoto, T., Yokoyama, M., Okano, T., Sakurai, Y., Fukushima, S., Okamoto, K., 
Kwon, G.S., 2000. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-l-aspartate) copolymer 
micelles: their pharmaceutical characteristics and biological significance. J Control Release 64, 
143-153. 
Lee, J., Lee, S.-J., Choi, J.-Y., Yoo, J.Y., Ahn, C.-H., 2005. Amphiphilic amino acid copolymers as 
stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci 24, 441-449. 
Lee, Y.Y., Wu, J.X., Yang, M., Young, P.M., van den Berg, F., Rantanen, J., 2011. Particle size 
dependence of polymorphism in spray-dried mannitol. Eur J Pharm Sci 44, 41-48. 
Li, J., Fu, Q., Liu, X., Li, M., Wang, Y., 2016. Formulation of nimodipine nanocrystals for oral 
administration. Arch Pharm Res 39, 202-212. 
Li, L., Huh, K.M., Lee, Y.-K., Kim, S.Y., 2010. Design of a multifunctional heparin-based nanoparticle 
system for anticancer drug delivery. Macromol Res 18, 153-161. 
Liang, Y., Binner, J., 2008. Effect of triblock copolymer non-ionic surfactants on the rheology of 
3 mol% yttria stabilised zirconia nanosuspensions. Ceram Int 34, 293-297. 
Liu, C.Z., Chang, J.H., Zhang, L., Xue, H.F., Liu, X.G., Liu, P., Fu, Q., 2016. Preparation and 
Evaluation of Diosgenin Nanocrystals to Improve Oral Bioavailability. AAPS PharmSciTech, 1-10. 
Matteucci, M.E., Brettmann, B.K., Rogers, T.L., Elder, E.J., Williams, R.O., 3rd, Johnston, K.P., 2007. 
Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. 
Mol Pharm 4, 782-793. 
Matteucci, M.E., Hotze, M.A., Johnston, K.P., Williams, R.O., 3rd, 2006. Drug nanoparticles by 
antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 22, 8951-8959. 
Matteucci, M.E., Paguio, J.C., Miller, M.A., Williams, R.O., Johnston, K.P., 2009. Highly 
Supersaturated Solutions from Dissolution of Amorphous Itraconazole Microparticles at pH 6.8. Mol 
Pharmaceut 6, 375-385. 
Okonya, J.F., Kolasa, T., Miller, M.J., 1995. Synthesis of the Peptide Fragment of Pseudobactin. J Org 
Chem 60, 1932-1935. 
Park, S.I., Lee, E.O., Yang, H.M., Park, C.W., Kim, J.D., 2013. Polymer-hybridized liposomes of 
poly(amino acid) derivatives as transepidermal carriers. Colloids Surface B 110, 333-338. 
Peeters, J., Neeskens, P., Tollenaere, J.P., Van Remoortere, P., Brewster, M.E., 2002. Characterization 
of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm 
Sci 91, 1414-1422. 
Pu, X., Sun, J., Wang, Y., Wang, Y., Liu, X., Zhang, P., Tang, X., Pan, W., Han, J., He, Z., 2009a. 
Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm 379, 
167-173. 
Pu, X.H., Sun, J., Han, J.H., Lian, H., Zhang, P., Yan, Z.T., He, Z.G., 2013. Nanosuspensions of 
10-hydroxycamptothecin that can maintain high and extended supersaturation to enhance oral 
absorption: preparation, characterization and in vitro/in vivo evaluation. J Nanopart Res 15. 
Pu, X.H., Sun, J., Li, M., He, Z.G., 2009b. Formulation of Nanosuspensions as a New Approach for the 
Delivery of Poorly Soluble Drugs. Curr Nanosci 5, 417-427. 
Pu, X.H., Sun, J., Qin, Y.M., Zhang, X., Zhang, P., Yan, Z.T., He, Z.G., 2012. The Passive Targeting and 
the Cytotoxicity of Intravenous 10-HCPT Nanosuspension. Curr Nanosci 8, 762-766. 
Pu, Y., Zhang, L., Zheng, H., He, B., Gu, Z., 2014. Drug release of pH-sensitive 
poly(l-aspartate)-b-poly(ethylene glycol) micelles with POSS cores. Polym Chem 5, 463-470. 
Rabinow, B., Kipp, J., Papadopoulos, P., Wong, J., Glosson, J., Gass, J., Sun, C.S., Wielgos, T., White, 
R., Cook, C., Barker, K., Wood, K., 2007. Itraconazole IV nanosuspension enhances efficacy through 
altered pharmacokinetics in the rat. Int J Pharm 339, 251-260. 
Rex, J.H., Pfaller, M.A., Galgiani, J.N., Bartlett, M.S., Espinel-Ingroff, A., Ghannoum, M.A., Lancaster, 
M., Odds, F.C., Rinaldi, M.G., Walsh, T.J., Barry, A.L., 1997. Development of interpretive breakpoints 
for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation 
data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 24, 235-247. 
Sarnes, A., Kovalainen, M., Hakkinen, M.R., Laaksonen, T., Laru, J., Kiesvaara, J., Ilkka, J., Oksala, O., 
Ronkko, S., Jarvinen, K., Hirvonen, J., Peltonen, L., 2014. Nanocrystal-based per-oral itraconazole 
delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug 
absorption. J Control Release 180, 109-116. 
Shah, S.M., Ullah, F., Khan, S., Shah, S.M., de Matas, M., Hussain, Z., Minhas, M.U., AbdEl-Salam, 
N.M., Assi, K.H., Isreb, M., 2016. Smart nanocrystals of artemether: fabrication, characterization, and 
comparative in vitro and in vivo antimalarial evaluation. Drug Des Dev Ther 10, 3837-3850. 
Wang, Y., Han, X., Wang, J., Wang, Y., 2016. Preparation, characterization and in vivo evaluation of 
amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization 
method. Int J Pharm 505, 35-41. 
Wang, Y., Zheng, Y., Zhang, L., Wang, Q., Zhang, D., 2013. Stability of nanosuspensions in drug 
delivery. J Control Release 172, 1126-1141. 
Wlaz, P., Knaga, S., Kasperek, K., Wlaz, A., Poleszak, E., Jezewska-Witkowska, G., Winiarczyk, S., 
Wyska, E., Heinekamp, T., Rundfeldt, C., 2015. Activity and Safety of Inhaled Itraconazole 
Nanosuspension in a Model Pulmonary Aspergillus fumigatus Infection in Inoculated Young Quails. 
Mycopathologia 180, 35-42. 
Wong, J., Papadopoulos, P., Werling, J., Rebbeck, C., Doty, M., Kipp, J., Konkel, J., Neuberger, D., 
2006. Itraconazole suspension for intravenous injection: determination of the real component of 
complete refractive index for particle sizing by static light scattering. PDA J Pharm Sci Technol 60, 
302-313. 
Xu, J., Ma, Y., Xie, Y., Chen, Y., Liu, Y., Yue, P., Yang, M., 2016. Design and Evaluation of Novel Solid 
Self-Nanodispersion Delivery System for Andrographolide. AAPS PharmSciTech, 3. 
Yang, H., Teng, F., Wang, P., Tian, B., Lin, X., Hu, X., Zhang, L., Zhang, K., Zhang, Y., Tang, X., 2014. 
Investigation of a nanosuspension stabilized by Soluplus(R) to improve bioavailability. Int J Pharm 477, 
88-95. 
Zhao, Z.X., Gao, S.Y., Wang, J.C., Chen, C.J., Zhao, E.Y., Hou, W.J., Feng, Q., Gao, L.Y., Liu, X.Y., 
Zhang, L.R., Zhang, Q., 2012. Self-assembly nanomicelles based on cationic 
mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials 33, 6793-6807. 
Figure legends 
Fig. 1 TEM images of (A) crude ITZ, (B) ITZ-PBLA-Nanos before lyophilization and 
(C) ITZ-PBLA-Nanos after lyophilization 
Fig. 2 X-ray diffraction pattern of (A) the crude ITZ; (B) blank excipients (the 
mixture of PEG-PBLA and mannitol); (C) physical mixture of ITZ and PEG-PBLA; 
F(D) lyophilized ITZ-PBLA-Nanos 
Fig. 3 DSC diagram of (A) the crude ITZ; (B) blank excipients (the mixture of 
PEG-PBLA and mannitol); (C) physical mixture of ITZ and PEG-PBLA; (D) 
lyophilized ITZ-PBLA-Nanos 
Fig. 4 In vitro dissolution of the crude ITZ suspension, Sporanox® injection and 
ITZ-PBLA-Nanos 
Fig. 5 Stability of ITZ-PBLA-Nanos and ITZ-F68-Nanos in one week at room 
temperature and 4℃ 
Fig. 6 Dilution stability of ITZ-PBLA-Nanos and ITZ-F68-Nanos 
Fig. 7 The IR spectrums of F68 (A), PEG-PBLA (B), F68 stabilized nanosuspensions 
precipitation (C) and PEG-PBLA stabilized nanosuspensions precipitation (D) 
Fig. 8 Plasma stability of ITZ-PBLA-Nanos and ITZ-F68-Nanos 
Fig. 9 The results of antifungal activity against Candida albicans for two formulations. 
A: ITZ-PBLA-Nanos with different concentration; B: Sporanox® injection with 
different concentration; C: two formulations with 100 μg/mL and blank control 
Scheme. 1 Synthesis of amphiphilic block copolymer PEG-PBLA 
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Table 1 Stability of nanosuspensions stabilized by three copolymers with different molecular 
weight (mean s.d., n=3) 
Copolymers Size(nm) PDI Size after 7d (nm) PDI after 7d 
PBLA(1/10) 329.8±8.43 0.078±0.01 1816±17.5 1±0.23 
PBLA(1/25) 287±6.08 0.133±0.03 266.8±5.35 0.224±0.04 
PBLA(1/50) 301.4±7.3 0.137±0.015 353.3±9.01 0.505±0.037 
 
Table 2 Stability of nanosuspensions with the different drug/stabilizer ratio (mean s.d., n=3) 
Drug/stabilizer ratio Size(nm) PDI Size after 7d (nm) PDI after 7d 
2:1 478.1±8.23 0.563±0.016 536±9.06 0.755±0.02 
1:1 260.3±7.88 0.168±0.003 269.5±8.5 0.183±0.009 
1:2 324.9±6.97 0.472±0.024 367.1±7.56 0.536±0.019 
 
Table 3 The mean particle sizes and zeta potentials of different nanosuspensions 
Parameters 
Before/After lyophilization 
ITZ-PLBA-Nanos ITZ-F68-Nanos 
Size (nm) 262.1±7.13/283.3±5.89 274±7.83/292.6±6.59 
PDI 0.163±0.011/0.172±0.013 0.201±0.019/0.233±0.021 
Zeta potential(mV) -17.5±1.1/-18.4±1.9 -16.1±1.4/-15.4±0.79 
 
Table 4 Clinical observations in acute toxicity study 
Treatment ITZ dose 
(mg/kg) 
Incidence of death/ 
number of animals 
Immediate observations 
(within 1h of administration) 
Delayed observations 
(days 1-7 post-injection) 
Saline 0 0/6 None None 
     
Sporanox® 
Injection 
40 
70 
100 
130 
160 
1/6 
2/6 
5/6 
6/6 
6/6 
2 polyuria and 1 lethargy 
2 slight lethargy and 2 convulsions 
4 slight lethargy and irregular breathing 
3 irregular breathing and 3 convulsions 
5 lethargy and 3 convulsions 
None 
2 red paw, 1 polydipsia 
1 red paw, 1 polydipsia 
None 
None 
     
ITZ- 
PBLA- 
Nanos 
60 
110 
160 
210 
260 
0/6 
1/6 
2/6 
3/6 
6/6 
None 
1 convulsions 
4 polyuria, 2 lethargy 
5 polyuria, 4 convulsions 
6 lethargy, 2 polyuria, 6 convulsions 
None 
None 
2 red paw, 2 polydipsia 
2 black tail, 3 polydipsia 
None 
     
ITZ- 
F68- 
Nanos 
60 
110 
160 
210 
0/6 
2/6 
2/6 
4/6 
1 irregular breathing 
1 polyuria, 2 convulsions 
3 lethargy, 2 convulsions 
6 polyuria, 5 convulsions 
None 
None 
1 red paw, 2 black tail 
2 black tail, 3 polydipsia 
260 6/6 6 polyuria, 5 lethargy, 6 convulsions None 
 
Table 5 Results of antifungal activities of ITZ formulations by viable cell counting method (n=3, 
±s.d.) 
Concentration (μg/mL) 
Candida albicans (×109 cfu/mL) 
Nanosuspension Sporanox® injection Blank control 
10 10.87±0.43 12.78±0.19 
14.95±0.25 
25 8.5±0.36 11.15±0.24 
50 6.80±0.33 9.65±0.24 
100 5.45±0.14 7.93±0.35 
250 3.90±0.32 6.77±0.30 
 
